September 22, 2025

Changing the story of cancer – together

Three innovative cancer tests. One defining mission.

Exact Sciences

This isn’t just innovation – it’s impact.

With groundbreaking science, a powerful platform, and key collaborations, we’re reimagining what’s possible for patients and their families. The journey to transform cancer care has only just begun.

Colorectal cancer screening

The Cologuard Plus™ Test

Designed to improve performance without losing the simplicity and convenience of a use-at-home test, the Cologuard Plus test has unmatched noninvasive colorectal cancer screening accuracy.*1,2,3
Multi-cancer early detection

The Cancerguard™ Test

Designed to detect multiple cancers even in their earliest stages from a simple blood draw, the Cancerguard test helps find multiple cancers including the deadliest cancers earlier, when they’re more treatable.4,5
Molecular residual disease

The Oncodetect™ Test

A tumor-informed test, the Oncodetect test helps guide therapy decisions and monitor cancer recurrence – identifying signs of colorectal cancer recurrence up to two years earlier than imaging.6

Footnotes and references

  1. Based on relative comparison to published reports; not direct evidence from head-to-head comparisons with all other screening tests.

  1. Cologuard Plus Clinician Brochure. Exact Sciences Corporation. Madison, WI.
  2. Guardant Health. Shield Provider Brochure. Palo Alto, CA.
  3. Geneoscopy, Inc. ColoSense Clinician Brochure. St. Louis, MO.
  4. Cancerguard Clinician Brochure. Exact Sciences Corporation. Madison, WI.
  5. Data on file. Cancerguard Test development study. 2025. Bioinformatics, Exact Sciences, Madison, WI
  6. Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology.

Dive deeper into